Results 21 to 30 of about 11,291,129 (270)

Renal AA-amyloidosis in intravenous drug users - a role for HIV-infection? [PDF]

, 2012
Background: Chronic renal disease is a serious complication of long-term intravenous drug use (IVDU). Recent reports have postulated a changing pattern of underlying nephropathy over the last decades.
Grützmacher, Peter, Oliver Jung, Christoph Stephan, Markus Bickel, Peter Gruetzmacher, Kerstin Amann, Hans Stefan Haack, Jung, Oliver, Haack, Hans Stefan, Büttner, Maike, Stephan, Christoph, Bickel, Markus, Amann, Kerstin, Amann, Kerstin Ute, Betz, Christoph, Maike Buettner, Haack, Hans S., Christoph Betz   +17 more
core   +2 more sources

The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis [PDF]

, 2020
BACKGROUND: Immunoglobulin light chain (AL) amyloidosis is a rare, multi-systemic disorder characterized by two disease processes: an underlying plasma cell dyscrasia that provides the source of pathologic light chains, and the resulting organ ...
Lousada, I, Inaugural Amyloidosis Forum Panelists, .   +1 more
core   +1 more source

Baseline characteristics of AL amyloidosis patients.

, 2022
Baseline characteristics of AL amyloidosis patients.
Patricia Sorroche (14020175), Elsa Mercedes Nucifora (14020178), Maria Lourdes Posadas-Martinez (14020163), María Adela Aguirre (14020166), Erika Brulc (14020169), Mariana Fernandez (8904974), Gerardo Machnicki (52539), Maria Soledad Saez (14020172)   +7 more
core   +1 more source

Evaluation of peripheral amyloid neuropathy

Неврология, нейропсихиатрия, психосоматика, 2021
Symptoms of peripheral nervous system (PNS) damage are common clinical manifestations of systemic amyloidosis. Peripheral amyloid neuropathy is characterized by a progressive course, leading to the disability of patients; however, the current ...
O. E. Zinovyeva, E. I. Safiulina, N. S. Shcheglova, Z. V. Surnina, A. M. Nosovskiy   +4 more
doaj   +1 more source

Severe Obstructive Cholestasis and Hypercalcemia Caused by Light-Chain Amyloidosis: A Case Report [PDF]

Iranian Journal of Medical Sciences, 2022
Gastrointestinal amyloidosis is a condition caused by the deposition of extracellular protein fragments. It can be associated with complex and diverse pathways and can have numerous manifestations and etiologies.
Zahra Davoudi, Farahnaz Bidari, Elena Jamali, Shahriar Nikpour   +3 more
doaj   +1 more source

Prognosis and Staging of AL Amyloidosis [PDF]

Acta Haematologica, 2020
The treatment options for systemic light chain amyloidosis (AL) are currently widening in an unprecedented way, brought about by an expanding arsenal of anti-myeloma therapy as well as by novel approaches to target toxic light chains and, most recently, deposited amyloid directly.
Tobias, Dittrich, Christoph, Kimmich, Ute, Hegenbart, Stefan O, Schönland   +3 more
openaire   +2 more sources

Search for AL amyloidosis risk factors using Mendelian randomization. [PDF]

, 2023
In amyloid light chain (AL) amyloidosis, amyloid fibrils derived from immunoglobulin light chain are deposited in many organs, interfering with their function. The etiology of AL amyloidosis is poorly understood. Summary data from genome-wide association
Chattopadhyay, S, Schmidt, B, Goldschmidt, H, Milani, P, Jöckel, K-H, Merlini, G, Försti, A, Rowcieno, D, Hegenbart, U, Wechalekar, A, Palladini, G, Hemminki, K, Hoffmann, P, Nöthen, MM, Hawkins, P, Schönland, SO, Saunders, CN, Landi, S, Houlston, R, Huhn, S, Weinhold, N   +20 more
core   +2 more sources

Purpuric halo around hemangioma as a clue for primary systemic amyloidosis: Case report and review of literature

Dermatologica Sinica, 2018
Mucocutaneous lesion appears in up to 40% of patients with primary systemic amyloidosis (AL amyloidosis). The cutaneous signs may be co-expressed with other organ involvement or even solely presented as the first clue.
Yin-Shuo Chang, Kuo-Hsien Wang, Hsiou-Hsin Tsai, Chung-Hong Hu, Jan-Show Chu   +4 more
doaj   +1 more source

Strong positive light chain immunostaining in a patient with transthyretin amyloidosis

Hematology, 2023
The two most common systemic amyloidosis types are immunoglobulin light chain (AL) and amyloid transthyretin (ATTR) amyloidosis, in which the precursor proteins responsible for amyloidosis are light chain and transthyretin, respectively.
Jiao Chen, Haifei Chen, Lingyun Zhou, Danbo Liu, Fang Du, Hongxian Xiang   +5 more
doaj   +1 more source

Supportive Care in AL Amyloidosis [PDF]

Acta Haematologica, 2020
Immunoglobulin light-chain (AL) amyloidosis is a systemic disease characterized by the production and deposition of light chain-derived amyloid fibrils in different organs. Prompt treatment directed to the underlying plasma cell clone is crucial in order to achieve a rapid, deep and durable hematologic response.
M Teresa, Cibeira, José T, Ortiz-Pérez, Luis F, Quintana, Carlos, Fernádez de Larrea, Natalia, Tovar, Joan, Bladé   +5 more
openaire   +2 more sources